News und Analysen
Lonza Q1 2025 Qualitative Update: Strong Performance Across All Businesses in Line with Expectations for Full-Year 2025
Puma Biotechnology Reports First Quarter Financial Results
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced financial results for the first quarter ended March 31, 2025. Unless otherwise stated, all comparisons are for the
Silence Therapeutics Reports First Quarter 2025 Financial Results and Recent Business Highlights
Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), a global clinical-stage company developing novel siRNA (short interfering RNA) therapies, today reported its financial results
Xencor Reports First Quarter 2025 Financial Results
Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, today reported financial results for the
Charles River Laboratories Announces First-Quarter 2025 Results
Charles River Laboratories International, Inc. (NYSE: CRL) today reported its results for the first quarter of 2025. For the quarter, revenue was $984.2 million, a decrease of 2.7% from $1,011.6
Global ICON survey shows need for more efficient obesity clinical trial design to realise full potential of next-gen multi-indication therapies
ICON plc, (NASDAQ: ICLR) a world-leading clinical research organisation powered by healthcare intelligence, today released the findings of a survey of 155 biotech and pharma professionals from
Charles River Laboratories Announces Governance Updates and Strategic Review to Enhance Long-Term Stockholder Value
Charles River Laboratories International, Inc. (NYSE: CRL) today announced that four new directors will join its Board of Directors and that four long-time members of the Board will not seek
EQS-News: Formycon invites to conference call on the results of the first quarter of 2025 and announces participation in international investor conferences
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that on May 5, 2025, the Compensation Committee of Puma’s Board of Directors approved the grant of inducement
Sangamo Therapeutics Announces First Quarter 2025 Earnings Call
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced that the company has scheduled the release of its first quarter 2025 financial results after the markets close
Sangamo Therapeutics Announces Important Derisking Milestones in Pathway to Anticipated BLA Submission for ST-920 in Fabry Disease
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced important derisking events in the pathway to a planned BLA submission for isaralgagene civaparvovec, or
Silence Therapeutics Welcomes Tim McInerney to Board of Directors
Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), a global clinical-stage company developing novel siRNA (short interfering RNA) therapies, today announced the appointment of Tim
Sensorion Announces its Participation in the American Society of Cell and Gene Therapy (ASGCT) Annual Meeting
Regulatory News:
Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company specializing in the development of novel therapies to restore, treat and prevent hearing loss
Aurinia Pharmaceuticals to Release First Quarter 2025 Financial and Operational Results on May 12, 2025
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today announced that it will release first quarter 2025 financial and operational results before markets open on May 12, 2025.
EQS-News: Immunic to Participate in Scientific and Industry Conferences in May
Savara Announces Participation in the Upcoming Citizens Life Sciences Conference
Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that members of the management team will be hosting 1x1
ICON Reports First Quarter 2025 Results
ICON plc (NASDAQ: ICLR), a world-leading clinical research organization powered by healthcare intelligence, today reported its financial results for the first quarter ended March 31, 2025.
CEO
EQS-Adhoc: BRAIN Biotech AG reports preliminary Q2 figures and forecasts a more conservative development for the second half of the fiscal year 2024/25
Glass Lewis Recommends That Aurinia Shareholders Vote “FOR” All Proposals at 2025 Annual General Meeting
Aurinia Pharmaceuticals Inc. (“Aurinia” or the “Company”) (NASDAQ: AUPH) today announced that leading independent proxy advisor Glass, Lewis & Co. LLC (“Glass Lewis”) has recommended that Aurinia
EQS-News: Immunic Announces Vidofludimus Calcium Reduced Risk of Disability Worsening by 30% in Primary Progressive Multiple Sclerosis Patients from Phase 2 CALLIPER Trial
EQS-News: Equity (NAV) increases by almost EUR 27 million to EUR 277.9 million, corresponding to EUR 64.90 per share. EBIT increases by EUR 2.75 million to EUR 33.0 million. The equity ratio rises to 95.5%.
Xencor Announces Positive Interim Results From First-in-Human Healthy Volunteer Study of XmAb942, a High-Potency Extended Half-Life Anti-TL1A Antibody, in Development for Treatment of Inflammatory Bowel Disease
Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, today announced positive interim results
EQS-News: Abivax Announces Completion of Enrollment for the Phase 3 ABTECT Trials in Patients with Moderately to Severely Active Ulcerative Colitis
Charles River Announces Inaugural Advanced Therapy Incubator Program Cohort
Charles River Laboratories International, Inc. (NYSE: CRL) today announced the initial cohort of its Charles River Incubator Program (CIP). Launched in December 2024, the program offers early-stage
ISS Recommends That Aurinia Shareholders Vote “FOR” All Proposals at 2025 Annual General Meeting
Aurinia Pharmaceuticals Inc. (“Aurinia” or the “Company”) (NASDAQ: AUPH) today announced that leading independent proxy advisor Institutional Shareholder Services (“ISS”) has recommended that